[1]邓少伟,赖彦华,周厚富.肝细胞癌精准肝切除在基层医院的应用研究[J].医学信息,2024,37(12):98-101106.[doi:10.3969/j.issn.1006-1959.2024.12.021]
 DENG Shao-wei,LAI Yan-hua,ZHOU Hou-fu.Application of Precise Hepatectomy for Hepatocellular Carcinoma in Primary Hospitals[J].Journal of Medical Information,2024,37(12):98-101106.[doi:10.3969/j.issn.1006-1959.2024.12.021]
点击复制

肝细胞癌精准肝切除在基层医院的应用研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年12期
页码:
98-101106
栏目:
论著
出版日期:
2024-06-15

文章信息/Info

Title:
Application of Precise Hepatectomy for Hepatocellular Carcinoma in Primary Hospitals
文章编号:
1006-1959(2024)11-0098-05
作者:
邓少伟赖彦华周厚富
(1.钟山县人民医院普通外科,广西 钟山 542699;2.广西壮族自治区人民医院移植科,广西 南宁 530021)
Author(s):
DENG Shao-weiLAI Yan-huaZHOU Hou-fu
(1.Department of General Surgery,the People’s Hospital of Zhongshan County,Zhongshan 542699,Guangxi,China;2.Department of Transplantation,the People’s Hospital of Guangxi Zhuang Autonomous Region,Nanning 530021,Guangxi,China)
关键词:
精准肝切除肝细胞癌常规肝切除
Keywords:
Precision hepatectomyHepatocellular carcinomaConventional hepatectomy
分类号:
R9735.7
DOI:
10.3969/j.issn.1006-1959.2024.12.021
文献标志码:
A
摘要:
目的 探讨基层医院开展精准肝切除治疗肝细胞癌的可行性。方法 回顾性分析2010年1月-2017年12月钟山县人民医院完成的188例行开放性肝切除的肝细胞癌患者资料,根据手术方式分为精准肝切除术组和常规肝切除术组,术后随访5年,比较两组手术耗时、术中出血量、术中输血量、住院时间、术后第3天转氨酶和总胆红素、并发症及生存率。结果 纳入精准肝切除术组95例,常规肝切除术组93例。两组手术时间、术中输血例数以及并发症比较,差异无统计学意义(P>0.05);精准肝切除术组术中出血量,住院时间,术后第3天血清谷丙转氨酶、谷草转氨酶和总胆红素低于常规肝切除术组(P<0.05);两组术后1、3、5年总体生存率比较,差异无统计学意义(P>0.05);精准肝切除术组后1、3、5年无瘤生存率高于常规肝切除术组(P<0.05)。结论 精准肝切除术比常规肝切除术根治肝细胞癌具有手术创伤小、术后肝功能恢复快、无瘤生存率高等明显优势,值得在基层医院应用。
Abstract:
Objective To explore the feasibility of precise hepatectomy in the treatment of hepatocellular carcinoma in primary hospitals.Methods The clinical data of 188 patients with hepatocellular carcinoma who underwent open hepatectomy in the People’s Hospital of Zhongshan County from January 2010 to December 2017 were retrospectively analyzed. According to the surgical methods, the patients were divided into precise hepatectomy group and conventional hepatectomy group. The patients were followed up for 5 years. The operation time, intraoperative blood loss, intraoperative blood transfusion, hospitalization time, transaminase and total bilirubin on the 3rd day after operation, complications and survival rate were compared between the two groups.Results There were 95 cases in the precise hepatectomy group and 93 cases in the conventional hepatectomy group. There was no significant difference in operation time, the number of intraoperative blood transfusion cases and complications between the two groups (P>0.05). The intraoperative blood loss, hospitalization time, serum alanine aminotransferase, aspartate aminotransferase and total bilirubin on the 3rd day after operation in the precise hepatectomy group were lower than those in the conventional hepatectomy group (P<0.05). There was no significant difference in the 1-, 3-, and 5-year overall survival rates between the two groups(P>0.05). The 1-, 3- and 5-year free survival rates in the precise hepatectomy group were higher than those in the conventional hepatectomy group(P<0.05).Conclusion Compared with conventional hepatectomy, precise hepatectomy has the obvious advantages of less surgical trauma, faster postoperative liver function recovery and higher free survival rate, which is worthy of application in primary hospitals.

参考文献/References:

[1]Konyn P,Ahmed A,Kim D.Current epidemiology in hepatocellular carcinoma [J].Expert Rev Gastroenterol Hepatol,2021,15(11):1295-1307.[2]Kaibori M,Kon M,Kitawaki T,et al.Comparison of anatomic and non-anatomic hepatic resection for hepatocellular carcinoma [J].J Hepatobiliary Pancreat Sci,2017,24(11):616-626.[3]Cutolo C,Fusco R,Simonetti I,et al.Imaging Features of Main Hepatic Resections: The Radiologist Challenging [J].J Pers Med,2023,13(1):134.[4]A J,Zhang J,Chai J,et al.Comparison of the Efficacy of Anatomic and Non-anatomic Hepatectomy for Hepatic Alveolar Echinococcosis: Clinical Experience of 240 Cases in a Single Center [J].Front Public Health,2021,9:816704.[5]Liu J,Zhuang G,Bai S,et al.The Comparison of Surgical Margins and Type of Hepatic Resection for Hepatocellular Carcinoma With Microvascular Invasion [J].Oncologist,2023:oyad124.[6]Liu H,Hu FJ,Li H,et al.Anatomical vs nonanatomical liver resection for solitary hepatocellular carcinoma: A systematic review and meta-analysis [J].World J Gastrointest Oncol,2021,13(11):1833-1846.[7]Kaibori M,Matsui Y,Hijikawa T,et al.Comparison of limited and anatomic hepatic resection for hepatocellular carcinoma with hepatitis C [J].Surgery,2006,139(3):385-394.[8]Sato N,Marubashi S.What is the optimal surgical treatment for hepatocellular carcinoma beyond the debate between anatomical versus non-anatomical resection? [J].Surg Today,2022,52(6):871-880.[9]Liao K,Yang K,Cao L,et al.Laparoscopic Anatomical Versus Non-anatomical hepatectomy in the Treatment of Hepatocellular Carcinoma: A randomised controlled trial [J].Int J Surg,2022,102:106652.[10]Cazauran JB,Paris L,Rousset P,et al. Anatomy of the Right Anterior Sector of the Liver and Its Clinical Implications in Surgery [J].J Gastrointest Surg,2018,22(10):1819-1831.[11]戴朝六,赵闯,徐锋.国内外腹腔镜肝切除术相关指南解读与比较[J].中国实用外科杂志,2017,37(5):539-542.[12]Kang KJ,Ahn KS.Anatomical resection of hepatocellular carcinoma: A critical review of the procedure and its benefits on survival [J].World J Gastroenterol,2017,23(7):1139-1146.[13]Zhou JM,Zhou CY,Chen XP,et al.Anatomic resection improved the long-term outcome of hepatocellular carcinoma patients with microvascular invasion: A prospective cohort study [J].World J Gastrointest Oncol,2021,13(12):2190-2202.[14]Shindoh J,Kobayashi Y,Umino R,et al.Successful Anatomic Resection of Tumor-Bearing Portal Territory Delays Long-Term Stage Progression of Hepatocellular Carcinoma [J].Ann Surg Oncol,2021,28(2):844-853.[15]Jia CK,Weng J,Chen YK,et al.Anatomic resection of liver segments 6-8 for hepatocellular carcinoma [J].World J Gastroenterol,2014,20(15):4433-4439.[16]Kang WH,Kim KH,Jung DH,et al.Long-term results of laparoscopic liver resection for the primary treatment of hepatocellular carcinoma: role of the surgeon in anatomical resection [J].Surg Endosc,2018,32(11):4481-4490.[17]王锦祥,李晓辉,刘特彬,等.吲哚菁绿荧光融合影像引导在腹腔镜解剖性肝切除术中的应用研究[J].江西医药,2021,56(1):42-48.[18]Tomassini F,Scuderi V,Colman R,et al.The single surgeon learning curve of laparoscopic liver resection: A continuous evolving process through stepwise difficulties [J].Medicine (Baltimore),2016,95(43):e5138.[19]Yamamoto Y,Ikoma H,Morimura R,et al.Clinical analysis of anatomical resection for the treatment of hepatocellular carcinoma based on the stratification of liver function [J].World J Surg,2014,38(5):1154-1163.[20]牟晓峰,王毅军.精准肝切除时代下肝脏切面的选择[J].医学信息,2023,36(6):185-188.[21]Gavriilidis P,Edwin B,Pelanis E,et al.Navigated liver surgery: State of the art and future perspectives [J]. Hepatobiliary Pancreat Dis Int,2022,21(3):226-233.[22]Ye R,Xie Y,Zhong D,et al.Effect of digital three-dimensional reconstruction technique combined with indocyanine green (ICG) excretion test for precision hepatectomy in primary liver cancer [J].Am J Transl Res,2023,15(5):3511-3520.

相似文献/References:

[1]王利娜,赵雪梅,徐云霞,等.磁共振扩散张量成像在肝细胞癌及 肝转移瘤鉴别诊断价值研究[J].医学信息,2018,31(09):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
 WANG Li-na,ZHAO Xue-mei,XU Yun-xia,et al.Diagnostic Value of Magnetic Resonance Diffusion Tensor Imaging in Hepatocellular Carcinoma and Liver Metastases[J].Journal of Medical Information,2018,31(12):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
[2]刘 冰,杨 帅,费锡斌,等.GPC-3联合CK-19免疫组化检测在肝细胞癌诊断及鉴别诊断中的应用[J].医学信息,2019,32(23):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
 LIU Bing,YANG Shuai,FEI Xi-bin,et al.Application of GPC-3 Combined with CK-19 Immunohistochemical Detection in Diagnosis and Differential Diagnosis of Hepatocellular Carcinoma[J].Journal of Medical Information,2019,32(12):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
[3]刘丽丽.CLCVP对肝细胞癌行腹腔镜肝叶切除手术相关指标及肝门阻断时间的影响[J].医学信息,2020,33(19):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
 LIU Li-li.The Effect of CLCVP on the Operation-related Indexes and Port Occlusion Time in Patients with Hepatocellular Carcinoma Undergoing Laparoscopic Lobectomy[J].Journal of Medical Information,2020,33(12):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
[4]孙莹莹,龚先琼.中药单体治疗肝细胞癌的研究[J].医学信息,2021,34(09):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
 SUN Ying-ying,GONG Xian-qiong.Study on the Treatment of Hepatocellular Carcinoma with Chinese Medicine Monomer[J].Journal of Medical Information,2021,34(12):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
[5]林思其,张泽鑫,夏睿琪,等.三种miRNA对肝癌预后预测的生物信息学分析模型[J].医学信息,2022,35(03):81.[doi:10.3969/j.issn.1006-1959.2022.03.019]
 LIN Si-qi,ZHANG Ze-xin,XIA Rui-qi,et al.A Model of Three miRNA on the Prognosis Prediction of Hepatocellular Carcinomaby Bioinformatics Analysis[J].Journal of Medical Information,2022,35(12):81.[doi:10.3969/j.issn.1006-1959.2022.03.019]
[6]李一鸣,陈文翔,王 禹,等.肝癌预后模型的构建及其在免疫治疗中的作用研究[J].医学信息,2022,35(04):68.[doi:10.3969/j.issn.1006-1959.2022.04.018]
 LI Yi-ming,CHEN Wen-xiang,WANG Yu,et al.The Construction of a Prognostic Model for Hepatocellular Carcinomaand its Role in Immunotherapy[J].Journal of Medical Information,2022,35(12):68.[doi:10.3969/j.issn.1006-1959.2022.04.018]
[7]徐帅帅,高 斌.TACE与阿帕替尼联合治疗中晚期肝细胞癌的疗效及安全性分析[J].医学信息,2022,35(06):116.[doi:10.3969/j.issn.1006-1959.2022.06.028]
 XU Shuai-shuai,GAO Bin.Analysis of the Efficacy and Safety of TACE Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(12):116.[doi:10.3969/j.issn.1006-1959.2022.06.028]
[8]李文华,许传斌,崔景景,等.基于治疗前MR-T2WI影像组学特征预测肝细胞癌射频消融术后早期复发的价值[J].医学信息,2022,35(18):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
 LI Wen-hua,XU Chuan-bin,CUI Jing-jing,et al.The Value of Predicting Early Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Based on Pre-treatment MR-T2WI Radiomics Features[J].Journal of Medical Information,2022,35(12):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
[9]彭莉蓉,黎村艳,史 杨.肿瘤微环境免疫细胞中差异lncRNA对肝细胞癌预后的预测价值[J].医学信息,2022,35(20):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
 PENG Li-rong,LI Cun-yan,SHI Yang.The Predictive Value of Differential lncRNA in Tumor Microenvironment Immune Cells for the Prognosis of Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(12):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
[10]裴金仙,陈天狮,任巧晶,等.JAK2/STAT3通路在HBV相关肝细胞癌中表达及机制研究[J].医学信息,2022,35(24):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]
 PEI Jin-xian,CHEN Tian-shi,REN Qiao-jing,et al.The Expression and Mechanism of JAK2/STAT3 Pathway in HBV-related Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(12):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]

更新日期/Last Update: 1900-01-01